Do analysts prefer QNRX or SXTP?

60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 1,059.00%. Given 60 Degrees Pharmaceuticals' higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor QNRX or SXTP?

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 4 mentions for 60 Degrees Pharmaceuticals and 3 mentions for Quoin Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 0.94 beat Quoin Pharmaceuticals' score of 0.62 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 60 Degrees Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate FNCH or SXTP?

60 Degrees Pharmaceuticals has a consensus target price of $13.85, indicating a potential upside of 1,059.00%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to KPRX or SXTP?

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 4 mentions for 60 Degrees Pharmaceuticals and 3 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.01 beat 60 Degrees Pharmaceuticals' score of 0.94 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiora Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive 60 Degrees Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SXTP or INTS?

In the previous week, Intensity Therapeutics had 3 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 7 mentions for Intensity Therapeutics and 4 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 0.94 beat Intensity Therapeutics' score of -0.02 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 60 Degrees Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, SXTP or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than 60 Degrees Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 60 Degrees Pharmaceuticals $1.41M 2.25 -$7.36M -$8.92 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is SXTP or PHXM more profitable?

PHAXIAM Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. Company Net Margins Return on Equity Return on Assets 60 Degrees Pharmaceuticals -574.91% N/A -131.48% PHAXIAM Therapeutics N/A N/A N/A

60 Degrees Pharmaceuticals (SXTP) Competitors

$1.20 +0.02 (+1.27%)

Closing price 04:00 PM Eastern

Extended Trading

$1.17 -0.02 (-2.01%)

As of 07:59 PM Eastern

Compare

SXTP vs. QNRX, FNCH, KPRX, INTS, and PHXM

Should you buy 60 Degrees Pharmaceuticals stock or one of its competitors? 60 Degrees Pharmaceuticals's main competitors and comparable companies include Quoin Pharmaceuticals (QNRX), Finch Therapeutics Group (FNCH), Kiora Pharmaceuticals (KPRX), Intensity Therapeutics (INTS), and PHAXIAM Therapeutics (PHXM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does 60 Degrees Pharmaceuticals compare to Quoin Pharmaceuticals?

Quoin Pharmaceuticals (NASDAQ:QNRX) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 1,059.00%. Given 60 Degrees Pharmaceuticals' higher possible upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

60 Degrees Pharmaceuticals has higher revenue and earnings than Quoin Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A
60 Degrees Pharmaceuticals	$1.41M	2.25	-$7.36M	-$8.92	N/A

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 11.2% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Quoin Pharmaceuticals has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

Quoin Pharmaceuticals has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 4 mentions for 60 Degrees Pharmaceuticals and 3 mentions for Quoin Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 0.94 beat Quoin Pharmaceuticals' score of 0.62 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

60 Degrees Pharmaceuticals beats Quoin Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

60 Degrees Pharmaceuticals has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
60 Degrees Pharmaceuticals	$1.41M	2.25	-$7.36M	-$8.92	N/A

Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market.

Finch Therapeutics Group has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

60 Degrees Pharmaceuticals has a consensus target price of $13.85, indicating a potential upside of 1,059.00%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, 60 Degrees Pharmaceuticals had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 4 mentions for 60 Degrees Pharmaceuticals and 1 mentions for Finch Therapeutics Group. 60 Degrees Pharmaceuticals' average media sentiment score of 0.94 beat Finch Therapeutics Group's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Finch Therapeutics Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

60 Degrees Pharmaceuticals beats Finch Therapeutics Group on 9 of the 14 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Kiora Pharmaceuticals?

Kiora Pharmaceuticals (NASDAQ:KPRX) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 4 mentions for 60 Degrees Pharmaceuticals and 3 mentions for Kiora Pharmaceuticals. Kiora Pharmaceuticals' average media sentiment score of 1.01 beat 60 Degrees Pharmaceuticals' score of 0.94 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiora Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.70	-$10.84M	-$2.51	N/A
60 Degrees Pharmaceuticals	$1.41M	2.25	-$7.36M	-$8.92	N/A

Kiora Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 292.16%. 60 Degrees Pharmaceuticals has a consensus price target of $13.85, indicating a potential upside of 1,059.00%. Given 60 Degrees Pharmaceuticals' higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 0.5% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kiora Pharmaceuticals has a beta of -0.38, meaning that its stock price is 138% less volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, meaning that its stock price is 154% more volatile than the broader market.

Kiora Pharmaceuticals has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

Summary

60 Degrees Pharmaceuticals beats Kiora Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to Intensity Therapeutics?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Intensity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Intensity Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
Intensity Therapeutics	N/A	-116.61%	-94.01%

60 Degrees Pharmaceuticals currently has a consensus target price of $13.85, indicating a potential upside of 1,059.00%. Intensity Therapeutics has a consensus target price of $37.50, indicating a potential upside of 846.97%. Given 60 Degrees Pharmaceuticals' higher possible upside, equities research analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Intensity Therapeutics had 3 more articles in the media than 60 Degrees Pharmaceuticals. MarketBeat recorded 7 mentions for Intensity Therapeutics and 4 mentions for 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals' average media sentiment score of 0.94 beat Intensity Therapeutics' score of -0.02 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
60 Degrees Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60 Degrees Pharmaceuticals has a beta of 2.54, suggesting that its stock price is 154% more volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.76, suggesting that its stock price is 176% more volatile than the broader market.

60 Degrees Pharmaceuticals has higher revenue and earnings than Intensity Therapeutics. Intensity Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.25	-$7.36M	-$8.92	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A

Summary

Intensity Therapeutics beats 60 Degrees Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does 60 Degrees Pharmaceuticals compare to PHAXIAM Therapeutics?

60 Degrees Pharmaceuticals (NASDAQ:SXTP) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

PHAXIAM Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%.

Company	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%
PHAXIAM Therapeutics	N/A	N/A	N/A

In the previous week, 60 Degrees Pharmaceuticals had 4 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 4 mentions for 60 Degrees Pharmaceuticals and 0 mentions for PHAXIAM Therapeutics. 60 Degrees Pharmaceuticals' average media sentiment score of 0.94 beat PHAXIAM Therapeutics' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
60 Degrees Pharmaceuticals	Positive
PHAXIAM Therapeutics	Neutral

PHAXIAM Therapeutics has lower revenue, but higher earnings than 60 Degrees Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$1.41M	2.25	-$7.36M	-$8.92	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

60 Degrees Pharmaceuticals presently has a consensus price target of $13.85, indicating a potential upside of 1,059.00%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

60 Degrees Pharmaceuticals has a beta of 2.54, suggesting that its stock price is 154% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

Summary

60 Degrees Pharmaceuticals beats PHAXIAM Therapeutics on 8 of the 12 factors compared between the two stocks.

Get 60 Degrees Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SXTP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SXTP vs. The Competition

Export

Metric	60 Degrees Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.14M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	N/A	640.15	211.09	21.74
Price / Sales	2.25	743.87	602.98	92.99
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	-0.20	11.60	12.91	6.24
Net Income	-$7.36M	$2.77B	$3.45B	$347.60M
7 Day Performance	6.70%	0.17%	1.12%	1.07%
1 Month Performance	-18.15%	0.35%	1.79%	1.03%
1 Year Performance	-77.19%	161.52%	67.69%	20.77%

60 Degrees Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SXTP 60 Degrees Pharmaceuticals	3.4213 of 5 stars	$1.20 +1.3%	$13.85 +1,059.0%	-78.1%	$3.14M	$1.41M	N/A	3	News Coverage Earnings Report
QNRX Quoin Pharmaceuticals	0.7363 of 5 stars	$5.89 +10.1%	N/A	-17.0%	$11.83M	N/A	N/A	4	News Coverage Earnings Report
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
KPRX Kiora Pharmaceuticals	3.0915 of 5 stars	$2.64 +0.8%	$10.00 +278.8%	+4.0%	$11.67M	$16.02M	N/A	10	Earnings Report Short Interest Decrease
INTS Intensity Therapeutics	3.2964 of 5 stars	$4.16 -1.0%	$37.50 +801.4%	-44.8%	$11.24M	N/A	N/A	2,021	Earnings Report Analyst Forecast Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SXTP) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

60 Degrees Pharmaceuticals (SXTP) Competitors

SXTP vs. QNRX, FNCH, KPRX, INTS, and PHXM

How does 60 Degrees Pharmaceuticals compare to Quoin Pharmaceuticals?

Summary

How does 60 Degrees Pharmaceuticals compare to Finch Therapeutics Group?

Summary

How does 60 Degrees Pharmaceuticals compare to Kiora Pharmaceuticals?

Summary

How does 60 Degrees Pharmaceuticals compare to Intensity Therapeutics?

Summary

How does 60 Degrees Pharmaceuticals compare to PHAXIAM Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP vs. The Competition

60 Degrees Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

60 Degrees Pharmaceuticals (SXTP) Competitors

SXTP vs. QNRX, FNCH, KPRX, INTS, and PHXM

How does 60 Degrees Pharmaceuticals compare to Quoin Pharmaceuticals?

Do analysts prefer QNRX or SXTP?

Which has better earnings & valuation, QNRX or SXTP?

Do institutionals & insiders believe in QNRX or SXTP?

Is QNRX or SXTP more profitable?

Which has more volatility and risk, QNRX or SXTP?

Does the media favor QNRX or SXTP?

Summary

How does 60 Degrees Pharmaceuticals compare to Finch Therapeutics Group?

Do institutionals and insiders believe in FNCH or SXTP?

Which has higher earnings and valuation, FNCH or SXTP?

Which has more risk & volatility, FNCH or SXTP?

Is FNCH or SXTP more profitable?

Do analysts rate FNCH or SXTP?

Does the media favor FNCH or SXTP?

Summary

How does 60 Degrees Pharmaceuticals compare to Kiora Pharmaceuticals?

Does the media refer more to KPRX or SXTP?

Which has preferable valuation and earnings, KPRX or SXTP?

Do analysts rate KPRX or SXTP?

Do insiders and institutionals believe in KPRX or SXTP?

Which has more volatility & risk, KPRX or SXTP?

Is KPRX or SXTP more profitable?

Summary

How does 60 Degrees Pharmaceuticals compare to Intensity Therapeutics?

Do insiders & institutionals have more ownership in SXTP or INTS?

Is SXTP or INTS more profitable?

Do analysts recommend SXTP or INTS?

Does the media prefer SXTP or INTS?

Which has more volatility & risk, SXTP or INTS?

Which has better earnings and valuation, SXTP or INTS?

Summary

How does 60 Degrees Pharmaceuticals compare to PHAXIAM Therapeutics?

Do institutionals and insiders have more ownership in SXTP or PHXM?

Is SXTP or PHXM more profitable?

Does the media prefer SXTP or PHXM?

Which has higher valuation and earnings, SXTP or PHXM?

Do analysts prefer SXTP or PHXM?

Which has more risk and volatility, SXTP or PHXM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SXTP vs. The Competition

60 Degrees Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools